Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi
نویسندگان
چکیده
منابع مشابه
Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial☆☆☆
OBJECTIVE To describe medroxyprogesterone acetate (MPA) levels among Kenyan depot medroxyprogesterone acetate (DMPA) users in the FEM-PrEP HIV prevention trial, and to compare MPA levels between ARV for HIV prevention (treatment) and placebo groups. STUDY DESIGN We measured MPA in previously collected plasma samples from 63 Kenyan trial participants who used DMPA for one or two complete inter...
متن کاملDepot Medroxyprogesterone Acetate and Bone Density
The 2002 National Survey of Family Growth reported that 5.3% of all US women aged 15 through 44 currently using contraception used DMPA.1 Among contraceptors, 13.9% of those aged 15 to 19 and 10.1% of those aged 20 to 24 currently used DMPA compared with 1.6% of those aged 40 to 44.1 Decreasing rates of adolescent pregnancy between 1995 and 2002 are considered to be due in part to increased use...
متن کاملIncidence of galactorrhea in young women using Depot-Medroxyprogesterone Acetate.
Galactorrhea is rarely mentioned as a possible side effect of the use of Depot-Medroxyprogesterone Acetate (DMPA). Over the last few years, we have noticed an increased number of patients complaining of galactorrhea. A review of clinical data showed that between 1999 and 2005, 360 adolescents in our clinic used DMPA for at least 6 months. After medical follow-up, 13 (3.6%) of these patients wer...
متن کاملImproved continuation rate of depot-medroxyprogesterone acetate in adolescent mothers.
Poor compliance and high discontinuation rates of Depot-Medroxyprogesterone Acetate (DMPA) and other contraceptive methods are major factors in the continuing problem of adolescent pregnancy. In this study we attempted to determine if providing comprehensive health care for teen mothers and their babies would improve continuation rates of DMPA. Patients who started DMPA between 1/1/96 and 1/1/9...
متن کاملSubcutaneous depo-medroxyprogesterone acetate.
To cite: Cameron S. Journal of Family Planning and Reproductive Health Care 2013;39:75–77. INTRODUCTION Since 2004, a micronised formulation of depo-medroxyprogesterone acetate (DMPA) that is delivered as a subcutaneous injection has been available. It is currently in clinical use in the USA and in nine countries throughout Europe. As of March 2013 this product is being marketed in the UK as Sa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Contraception
سال: 2019
ISSN: 0010-7824
DOI: 10.1016/j.contraception.2019.07.144